Clinical and histopathological behaviour of incidental prostate adenocarcinoma
Abstract
A retrospective descriptive study was carried out in the "Capitán Roberto Rodríguez Fernández"General Hospital, in Morón to know the clinical and histopathological behaviour of Adenocarcinoma
of Incidental Prostate, in patients subjected to adenomectomy by the possible diagnose of
Prostatic Hyperplasia showing an incidence of 28,64%, with a predominance in white people and
ages between 71 and 80 years. In 95,5% the Digital Rectal Examination was normal and in
58,93% the Prostate-Specific Antigen was normal too, Gleason scores was in the classification of
low degree the predominance with 63,93% and a macroscopic tumoral focus with 60,71% with
positive surgical time allowed only 6 pieces 5,36%. In 4,46% coexised high grade (PIN AG)
intraepithelial neoplasia of the prostate and the predominant pathological statification was pT2to.
Downloads
References
Milanés Sánchez JL, Sánchez Iturriaga M, Martínez Ginarte G. Aspectos clínicos e histopatológicos del adenocarcinoma prostático en nuestro medio. Multimed [Internet]. 2009 [citado 16 Oct 2013]; 13(2): [aprox. 8 p.]. Disponible en: http://www.sabetodo.com/documentos/aspectos-clinicos-adenocarcinoma-13102010.pdf
Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999; 49(1): 33-64.
Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy: a multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol. 1996; 20(3):286-92.
Padilla Rodríguez AL. Lineamientos para el manejo, diagnóstico y reporte de cáncer de próstata en especímenes de prostatectomía radical. Patología. 2008; 46(3): 248-62.
Berna A, Vuruskan H. Clinicopathologic features of incidental prostatic adenocarcinoma in radical cystoprostatectomy specimens. World J Surg Oncol. 2011; 9:81.
Partin AW, Coffey DS. The molecular biology, endocrinology, and physiology of the prostate and seminal vesicles. In: Walsh PC, Retik AB, Vaughan ED, et al. eds. Campbell’s Urology. 8th ed. Philadelphia: Saunders; 2002. p. 1237-96.
McNeal JE. Normal and pathologic anatomy of prostate. Urology. 1981; 17[Suppl. 3]:11-16.
Picurelli Oltra L, Sendra Torres A, Fernández Rodríguez A, Ortega Villar F, Baixauli Martínez J, Tramoyeres Celma A. Incidental prostatic adenocarcinoma in the era of the PSA. Actas Urol Esp 1997; 21:354-356.
Krishnamurthi V, Klein EA, Levin HS. Probability of prostate cancer detection following diagnosis of PIN. J Urol 1997; 157:366-368.
Raviv G, Kiss R, Vanegas JP, et al. PIN: influence of clinical and pathological data on the detection of prostate cancer. J Urol 1996; 156:1050-1054.
Salas Cabrera R, Rodríguez Expósito CF, Sagué Larrea JL, Laurencio Mena A. Factores de Riesgo en el Cáncer de la Próstata. Criterios de expertos. Ciencias Holguín [Internet]. 2009 [citado 10Mar 2013]; 15(4): [aprox. 8 p.]. Disponible en: http://www.ciencias.holguin.cu/index.php/cienciasholguin/article/view/518
Williams H, Powell IJ. Epidemiology, pathology, and genetics of prostate cancer among African Americans compared with other ethnicities. Methods Mol Biol. 2009; 472:439 53.
Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: Geographical distribution and secular trends. Mol Nutr Food Res. 200953(2):171-184.
Súchil Bernal B. Epidemiología del cáncer de próstata. Clin Translat Oncol. 2011; 3(1): 11-21.
Instituto Nacional del Cáncer. Cáncer de la próstata: Tratamiento (PDQ®) [Internet]. 2009 [actualizado 12 Mar 2009; citado Jul 2010] [aprox. 6 pantallas]. Disponible en: http://www.cancer.gov/espanol/pdq/tratamiento/prostata/Patient
DeVita V, Hellman S, Rosemberg S.Cancers of the genitourinary system. En: Cancers Principles & Practice of Oncology. Philadelphia: Lippincott Williams & Wilkins; 2007.
Pérez Pérez R, Fajardo Pérez M, Orlando González N. El cáncer de próstata: un desafío constante para el Médico de Familia. Rev Cubana Med Gen Integr [Internet]. 2002 [citado 12 May 2009]; 18(5): [aprox. 9 p.].
Merayo Chalico CE, Sánchez Turati GJ, Santana Ríos Z, Pérez Becerra R, Saavedra Briones DV, Morales Montor JG, Pacheco Gahbler C, Calderón Ferro F. Prevalencia del cáncer de próstata incidental en el Hospital General “Dr. Manuel Gea González”. Rev Mex Urol 2009; 69(4):147-152.
Matthew R, Smith M. Effective treatment for early-stage prostate cancer possible, necessary, or both? N Engl J Med. 2011; 364:1770-1772.
Fernández Rosado E, Gómez Veiga F, Álvarez Castelo L, Ruibal Moldes M, Chantada Abal V, González Martín M. Estudio clínico-patológico sobre el cáncer de próstata incidental en pacientes intervenidos bajo el supuesto diagnóstico de HBP sintomática. Actas Urol Esp. 2006; 30 (1): 33-37.
Arrabal Polo MA, Jiménez Pacheco A, Mijan Ortiz JL, Arrabal Martín M, Valle Díaz de la Guardia F, López Carmona Pintado F, et al. Relación entre score Gleason biópsico y score Gleason tras prostatectomía radical en pacientes sometidos a biopsia sextante vs 12 cilindros. Arch Esp Urol. 2010; 63(9): 791-796.
Rincón Mayans A, Zudaire B, Brugarolas J, Rioja J, Zudaire J, Rosell D, et al. Cáncer de próstata localizado de alto riesgo tratado mediante prostatectomía radical. Pronóstico y estudio de variables influyentes. An Sist Sanit Navar. 2012; 35(1): 9-18.
Pascual Mateo C, Luján Galán M, Rodríguez García N, Llanes González L, Berenguer Sánchez A. Significado clínico de la neoplasia intraepitelial prostática y de la proliferación acinar focal atípica: relación con el cáncer de próstata. Actas Urol Esp. 2008; 32(7): 37-44.
Arzoz Fábregas M, Areal Calama J, Ibarz Servio L, Gago Ramos JL, Boix Orri R, Saladié Roig JM. Neoplasia intraepitelial prostática aislada y positividad para adenocarcinoma en la rebiopsia. Revisión de nuestra serie. Actas Urol Esp. 2005; 29(8): 21-30.
International Union Against Cancer (UICC). TNM Classification of Malignant Tumours. 6 ed. Maryland: Wiley; 2002.
Downloads
Published
How to Cite
Issue
Section
License
Those authors who have publications with this journal accept the following terms of the License CC Attribution-NonCommercial 4.0 International (CC BY-NC 4.0):
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes .
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
